Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease

• US 6,352,715 B1
• Filed: 06/12/2000
• Issued: 03/05/2002
• Est. Priority Date: 02/19/1998
• Status: Expired due to Term

• Current Assignee: Sagittarius Life Science Corp.
• Original Assignee: Sagittarius Life Science Corp.
• Inventors: Liu, Suying, Hwang, Kou Mark
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): GHALI, ISIS A D
• Application Number:
  US09/591,931
• Time in Patent Office: 631 Days
• Field of Search: 424/448, 424/449, 424/443, 514/286
• US Class Current: 424/448
• CPC Class Codes: A61K 31/439 the ring forming part of a bridged ring system, e.g. quinuclidine 8-azabicyclo [3.2.1] octanes A61K31/46
• CPC Class Codes: A61K 9/7061 Polyacrylates

Abstract

This invention relates to a novel transdermal drug delivery system whereby Huperzine A (“Hup A”), a naturally occurred Acetylcholine esterase inhibitor traditionally used to alleviate memory problem, is formulated for transdermal administration suitable for the treatment of Alzheimer'"'"'s Disease (“AD”) to increase the efficacy and convenience for outpatient care of AD patients. A controlled-release skin patch designed for once-a-week application of Hup A is provided for easy AD medication according to the invention.

Claims

1. A rate-controlled transdermal drug delivery device for transdermal delivery of Huperzine A at a therapeutically effective rate in a linear square root of time manner for up to at least 7 days to provide therapeutical benefits to patients with Alzheimer'"'"'s disease, comprising;

(a) a concentration of Huperzine A in an amount sufficient to enable transdermal delivery of said Huperzine A at said therapeutically effective rate of no less than 0.833-1.46 ug/cm².h to exhibit said therapeutical benefits;

(b) a solution of adhesive polymer in a concentration sufficient to form a Huperzine A dispersing pressure-sensitive adhesive with said concentration of Huperzine A wherein said solution of adhesive polymer is adjusted to a pH range in which said concentration of Huperzine A is predominantly in a neutral form to achieve transdermal delivery of said Huperzine A at said therapeutically effective rate in said linear square root of time manner for up to at least 7 days per one administration; and

(c) a sheet of drug-impermeable backing laminate added to support said Huperzine A dispersing pressure-sensitive.

2. The transdermal drug delivery device of claim 1 wherein said solution of adhesive polymer is polyacrylate.

3. The transdermal drug delivery device of claim 1 wherein said Huperzine A dispersing pressure-sensitive adhesive is a lipophilic, water absorbing adhesive.

4. The transdermal drug delivery device of claim 3 wherein said lipophilic adhesive is selected from the group consisting of esters with hydroxyl groups.

5. The transdermal drug delivery device of claim 1 wherein said range of pH is between 7 and 9.

13. The method of preparing an adhesive transdermal drug delivery device of claim 4 wherein said Huperzine A dispersing pressure-sensitive adhesive is a lipophilic, water absorbing adhesive.

14. The method of preparing an adhesive transdermal drug delivery device of claim 13 wherein said lipophilic, water absorbing adhesive is selected from the group consisting of esters with hydroxyl groups.

6. A method of preparing a rate-controlled adhesive transdermal drug delivery device suitable for transdermal delivery of Huperzine A at a therapeutically effective rate in a linear square root of time manner for up to at least 7 days to provide therapeutical benefits to patients with Alzheimer'"'"'s disease, comprising the steps of:

(a) weighing a concentration of Huperzine A in an amount sufficient to enable transdermal delivery of said Huperzine A at the therapeutically effective rate of no less than 0.833-1.46 ug/cm².h to exhibit said therapeutical benefits;

(b) dissolving said Huperzine A in a solution of adhesive polymer in presence of a suitable solvent to from a Huperzine A dispersing pressure-sensitive adhesive wherein said solution of adhesive polymer is in a pH range in which said Huperzine A is predominantly in a neutral form to achieve said rate-controlled transdermal delivery of Huperzine A at the therapeutically effective rate in said linear square root of time manner for up to at least 7 days per one administration; and

(c) adding a sheet of drug-impermeable backing laminate to support said Huperzine A dispersing pressure-sensitive adhesive.

7. The method of preparing an adhesive transdermal drug delivery device of claim 6 wherein said solution of adhesive polymer is polyacrylate.

8. The method of preparing an adhesive transdermal drug delivery device of claim 6 wherein said Huperzine A dispersing pressure-sensitive adhesive is a lipophilic, water absorbing adhesive.

9. The method of preparing an adhesive transdermal drug delivery device of claim 8 wherein said lipophilic, water absorbing adhesive is selected from the group consisting of esters with hydroxyl groups.

10. The method of preparing an adhesive transdermal drug delivery of claim 6 wherein said range of pH is between 7 and 9.

11. A method of providing therapeutical benefits of Huperzine A to a human patient diagnosed with Alzheimer'"'"'s disease, comprising:

(a) preparing a transdermal drug delivery device suitable for transdermal administration of said Huperzine A to said human patient, said transdermal drug delivery device comprising;

(i) a concentration of Huperzine A in an amount sufficient to enable transdermal delivery of said Huperzine A at a therapeutically effective rate at or higher than 0.833-1.46 ug/cm².h in a linear square root of time manner for up to at least 7 days;

(ii) a solution of adhesive polymer in a concentration sufficient to dissolve said concentration of Huperzine A to form a Huperzine A dispersing pressure-sensitive adhesive wherein said concentration of Huperzine A is adjusted to a pH range in which said Huperzine A is predominantly in a neutral form to achieve transdermal delivery of said Huperzine A at said therapeutically effective rate for up to at least 7 days;

(iii) a sheet of drug-impermeable backing laminate added to support said concentration of Huperzine A to form the dispersing pressure-sensitive; and

(b) administrating said human patient with said transdermal drug delivery device to provide said therapeutic benefits.

12. The method of preparing an adhesive transdermal drug delivery device of claim 11 wherein said solution of adhesive polymer is polyacrylate.

15. The method of preparing an adhesive transdermal drug delivery device of claim 11 wherein said range of pH is between 7 and 9.